Dallas, Texas 04/29/2014 (FINANCIALSTRENDS) – Horizon Pharma Inc (NASDAQ:HZNP) has finally moved forward on its acquisition spree, with its latest product acquisition – VIdara Therapeutics International now removed early than the May 1, 2014 waiting period.
Horizon Pharma Inc (NASDAQ:HZNP) has indicated that it received early termination of the scheduled waiting period as per the Hart-Scott-Rodino Antitrust Improvements Act. The focus was on the Vidara Therapeutics International Ltd. The phase of expansion for this drug maker is therefore indicative of better pipelines the company is expected to build in the near future.
Horizon Pharma Inc (NASDAQ:HZNP)has a market capital to the tune of $919.44 million and has been trading on the stock market at prices in the range of $12.88 low and $14.20 high. The 52 week trading range for this stock is $2.11 low and $18.30 high. EPS for this stock is -2.33 and its outstanding shares are to the tune of 68.56 million.
Horizon Pharma Inc (NASDAQ:HZNP) is a pharmaceutical which is involved in the use of biotechnology techniques to build and develop products and therapies which will bring higher relief as well as resolve medical conditions. Though, the company is currently aimed at finding solutions for medical conditions which do not have a solution as yet, its main areas of development include therapy and treatment for inflammatory diseases, pain as well as arthritis.
This biopharmaceutical company which is headquartered in Deerfield, Illinois, US is in the same league as other pharmaceuticals such as Astrazeneca, Pfizer as well as Amgen Inc. Other players in this line-up include- PozenInc, Dr.Reddy’s Laboratories as well as Merck & Co.
Other companies which compete with HZNP include Sanofi SA as well as Abbot Laboratories as well as Johnson & Johnson besides AbbVie Inc.
Post the new acquisition in place, the company can now begin to see further expansion into new markets which VIdara Therapeutics International is already involved in.